Clinical trial NCT02153788: Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
Official title: A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Insomnia
Keywords: Insomnia
HIV
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test two study drugs, one of which is temazepam (15mg) and one of which is a placebo (an inactive substance that looks just like the temazepam), to see if insomnia (trouble sleeping) can be reduced in patients with HIV infection. Placebos are given in research studies to try and make sure that subjects are responding to the effects of the study drug and not to other factors, like the attention they are receiving. If you decide to take part in this study, you will take 1 capsule of study drug every night approximately 30 minutes before bedtime for approximately 12 weeks.

This study is to test the study drug called temazepam for the treatment of insomnia (trouble sleeping) in patients with HIV infection. Temazepam has been approved by the FDA for the treatment of insomnia. However, because this study requires treatment for 12 weeks instead of the 7 to 10 days approved by the FDA, the use of temazepam is considered to be investigational in this study.


Eligibility criteria: Inclusion Criteria:

1. males or females age 18-69;
2. females must utilize an approved form of birth control during the study;
3. have at least a 3 month history of insomnia as defined in the DSM-IV criteria for primary insomnia;
4. self report \> 60 minutes of wakefulness after initial sleep onset on at least 4 nights of 7 consecutive nights;
5. self report \> 30 minutes of self-reported latency to sleep onset on at least 4 nights of 7 consecutive nights;
6. Self report \< 6.5 hours of total sleep time at least 4 nights of 7 consecutive nights;
7. be able to read, understand, and sign an informed consent form before entering into the study and must be willing to comply with all study procedures;
8. agree to participate for the entire study period (a total of approximately 6 months); and
9. provide documentation of HIV seropositivity and be enrolled in ongoing care for their HIV disease in an infectious disease clinic with their last examination not exceeding 3 months prior to screening date

Exclusion Criteria:

1. Have a clinically significant unstable medical abnormality, or history or presence of significant neurological disorders (including cognitive disorders), or frequent nightly urination, defined as \> 2 times per night;
2. Had a clinically significant illness, as determined by the Investigator, within 30 days of Initial Screening (Visit 1);
3. Have any clinically significant abnormal finding in physical examination, neurological assessment, or vital signs, as determined by the Investigator;
4. Have a known or exaggerated pharmacological sensitivity or hypersensitivity or intolerance to doxepin HCl, any tricyclic antidepressant or antihistamine, temazepam or any benzodiazepine;
5. Have a positive urine drug screen for amphetamines, benzodiazepines, barbiturates, cocaine, opiates, or cannabinoids at Initial Screening (Visit 1);
6. Self reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly;
7. Have a history of epilepsy or serious head injury;
8. Have been on current HAART or antiretroviral regimen for less than 1 month;
9. Have a recent history (within one year) of alcohol or drug abuse, or current evidence of substance dependence or abuse as defined by DSM-IV-TR criteria;
10. Have used temazepam for any indication within the 30 days prior to Initial Screening (Visit 1);
11. Have used any investigational drug within 30 days or five half-lives (whichever is longer) prior to Initial Screening (Visit 1), or plans to use an investigational drug (other than the study drug) during the study;
12. Current use of any of the following medications: antipsychotics, appetite suppressants, systemic corticosteroids, theophylline, respiratory stimulants and decongestants;
13. The following medications may be discontinued for the purpose of entry into the study provided the medication is taken at bedtime for the indication of sleep. If the indication is other than sleep, the medication cannot be discontinued for the purpose of entry into the study: anxiolytics, antidepressants, anticonvulsants, histamine-1 receptor antagonists (except for loratadine, desloratidine, and fexofenadine), narcotic analgesics, sedative/hypnotics (other than study drug) or OTC sleep aids;
14. Have symptoms consistent with the diagnosis of any other sleep disorder other than primary insomnia (e.g., sleep apnea, narcolepsy, periodic leg movements, restless leg syndrome, etc.);
15. Have a body mass index (BMI) greater than or equal to 34;
16. Have insomnia associated with circadian rhythm disturbances, such as night or rotating shift work or travel across more than four time zones in the 14 days before Initial Screening (Visit 1) or during the study;
17. Self reports intentional napping more than two times per week;
18. Have a variation in bedtime of more than three hours on five of seven consecutive nights as recorded on the sleep diary;
19. Have a history of non-adherence to treatment or clinical visit attendance; or,
20. subjects taking any benzodiazepine within 5 half-lives prior to the study baseline

Primary outcomes:
measure: Mean Change in the Insomnia Severity Index
timeFrame: Randomization to final study visit, approximately 12 weeks
Secondary outcomes:
measure: Mean Change in Self Reported Total Sleep Time
timeFrame: Randomization to final study visit, approximately 12 weeks
measure: Mean Change in Self-reported Total Sleep Time
timeFrame: Randomization to the end of the open label phase, approximately 1 week
measure: Mean Change in Piper Fatigue Score
timeFrame: Baseline, week 12
measure: Mean Change in the Hospital Anxiety and Depression Scale - Anxiety (HADS-A)
timeFrame: Baseline, week 12
measure: Mean Change in the Distress Thermometer
timeFrame: Baseline, week 12
measure: Mean Change in the Hospital Anxiety and Depression Scale - Depression (HADS-D)
timeFrame: Baseline, week 12
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Andrew Krystal, MD
role: PRINCIPAL_INVESTIGATOR
References: